JP2013519083A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013519083A5 JP2013519083A5 JP2012551689A JP2012551689A JP2013519083A5 JP 2013519083 A5 JP2013519083 A5 JP 2013519083A5 JP 2012551689 A JP2012551689 A JP 2012551689A JP 2012551689 A JP2012551689 A JP 2012551689A JP 2013519083 A5 JP2013519083 A5 JP 2013519083A5
- Authority
- JP
- Japan
- Prior art keywords
- flc
- infection
- amount
- light chain
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 14
- 208000015181 infectious disease Diseases 0.000 claims 10
- 238000003149 assay kit Methods 0.000 claims 4
- 230000004083 survival effect Effects 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000037384 Clostridium Infections Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 206010057190 Respiratory tract infections Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000004848 nephelometry Methods 0.000 claims 1
- 206010034674 peritonitis Diseases 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000019206 urinary tract infection Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1001950.3 | 2010-02-05 | ||
| GBGB1001950.3A GB201001950D0 (en) | 2010-02-05 | 2010-02-05 | Infection prognostic assay |
| PCT/GB2011/050197 WO2011095820A1 (en) | 2010-02-05 | 2011-02-04 | Infection prognostic assay |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013519083A JP2013519083A (ja) | 2013-05-23 |
| JP2013519083A5 true JP2013519083A5 (enExample) | 2014-04-10 |
| JP5818818B2 JP5818818B2 (ja) | 2015-11-18 |
Family
ID=42082582
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012551687A Active JP5818817B2 (ja) | 2010-02-05 | 2011-02-04 | がん予後診断アッセイ |
| JP2012551689A Active JP5818818B2 (ja) | 2010-02-05 | 2011-02-04 | 感染症予後診断アッセイ |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012551687A Active JP5818817B2 (ja) | 2010-02-05 | 2011-02-04 | がん予後診断アッセイ |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20130217030A1 (enExample) |
| EP (1) | EP2531857B1 (enExample) |
| JP (2) | JP5818817B2 (enExample) |
| CN (2) | CN102859361B (enExample) |
| GB (1) | GB201001950D0 (enExample) |
| WO (1) | WO2011095820A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2519564A (en) * | 2013-10-24 | 2015-04-29 | Shared Band Ltd | Multicast transmission over bonded broadband |
| WO2016016897A1 (en) * | 2014-07-30 | 2016-02-04 | Smadar Avigad | Prognostic methods and systems of treatment for acute lymphoblastic leukemia |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4792529A (en) * | 1985-10-18 | 1988-12-20 | University Of Rochester | Immunoassay of free kappa light chains for the detection of multiple sclerosis |
| IT1216698B (it) * | 1988-04-01 | 1990-03-08 | New Scient Co Spa | Metodo per la determinazione della presenza di catene leggere libere in campioni di urina, complesso di preparati per l'esecuzione del metodo, e relativo reagente. |
| EP0862584B1 (en) | 1995-11-03 | 2004-12-22 | The Binding Site Limited | Production of antibodies |
| US6322788B1 (en) * | 1998-08-20 | 2001-11-27 | Stanley Arthur Kim | Anti-bacterial antibodies and methods of use |
| US20040018576A1 (en) * | 2002-07-24 | 2004-01-29 | Dematteo Todd M. | Bence Jones protein testing cassette |
| JP4438455B2 (ja) * | 2004-03-04 | 2010-03-24 | ヤマサ醤油株式会社 | 遊離ヒトイムノグロブリン軽鎖の測定法及びキット |
| WO2005116651A2 (en) * | 2004-05-24 | 2005-12-08 | Diasys Corporation | Method and device for testing for bence-jones protein |
| AU2005304320A1 (en) * | 2004-11-12 | 2006-05-18 | Board Of Regents, The University Of Texas System | Methods of treating hematological malignancies with nucleoside analog drugs |
| GB0501741D0 (en) * | 2005-01-27 | 2005-03-02 | Binding Site The Ltd | Antibody |
| EP2267449B1 (en) * | 2005-04-12 | 2014-01-08 | Akira Matsumori | Biomarker for diagnosing heart failure and the use thereof |
| JP2007292661A (ja) * | 2006-04-26 | 2007-11-08 | Akira Matsumori | 活動性心筋炎の検出方法および検出試薬 |
| GB0801609D0 (en) * | 2008-01-29 | 2008-03-05 | Binding Site The Ltd | Hevylite diagnostic stain |
-
2010
- 2010-02-05 GB GBGB1001950.3A patent/GB201001950D0/en not_active Ceased
-
2011
- 2011-02-04 JP JP2012551687A patent/JP5818817B2/ja active Active
- 2011-02-04 US US13/576,099 patent/US20130217030A1/en not_active Abandoned
- 2011-02-04 CN CN201180008402.0A patent/CN102859361B/zh active Active
- 2011-02-04 US US13/576,063 patent/US20130149792A1/en not_active Abandoned
- 2011-02-04 CN CN201180008422.8A patent/CN102859362B/zh active Active
- 2011-02-04 WO PCT/GB2011/050197 patent/WO2011095820A1/en not_active Ceased
- 2011-02-04 EP EP11702698.9A patent/EP2531857B1/en active Active
- 2011-02-04 JP JP2012551689A patent/JP5818818B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Guery et al. | Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. Epidemiology and diagnosis | |
| Bruns et al. | Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia | |
| Papp et al. | Acute phase proteins in the diagnosis and prediction of cirrhosis associated bacterial infections | |
| Abdel-Razik et al. | Ascitic fluid calprotectin and serum procalcitonin as accurate diagnostic markers for spontaneous bacterial peritonitis | |
| Jitpean et al. | Increased concentrations of Serum amyloid A in dogs with sepsis caused by pyometra | |
| Viskari et al. | Maternal enterovirus infection as a risk factor for type 1 diabetes in the exposed offspring | |
| Mauri et al. | Alveolar pentraxin 3 as an early marker of microbiologically confirmed pneumonia: a threshold-finding prospective observational study | |
| Ueda et al. | Diagnostic accuracy of the E-plate serum antibody test kit in detecting Helicobacter pylori infection among Japanese children | |
| JP2012509477A5 (enExample) | ||
| JP2011085586A5 (enExample) | ||
| Zhang et al. | Detection of sepsis in patient blood samples using CD64 expression in a microfluidic cell separation device | |
| Contenti et al. | Presepsin versus other biomarkers to predict sepsis and septic shock in patients with infection defined by Sepsis-3 criteria: the PREDI study of diagnostic accuracy | |
| Ivaska et al. | Aetiology of febrile pharyngitis in children: potential of myxovirus resistance protein A (MxA) as a biomarker of viral infection | |
| Yu et al. | Distinction between bacterial and viral infections by serum measurement of human neutrophil lipocalin (HNL) and the impact of antibody selection | |
| CN103562725B (zh) | 川崎病的诊断标志物和治疗靶点 | |
| Wu et al. | Procalcitonin as a diagnostic biomarker for septic shock and bloodstream infection in burn patients from the Formosa Fun Coast dust explosion | |
| Weh et al. | Discriminatory potential of C-reactive protein, cytokines, and fecal markers in infectious gastroenteritis in adults | |
| JP2013519083A5 (enExample) | ||
| Woodhouse et al. | Harnessing the host response for precision infectious disease diagnosis | |
| Teng et al. | Outcome prediction using the Mortality in Emergency Department Sepsis score combined with procalcitonin for influenza patients | |
| CA2955214A1 (en) | Diagnosis and treatment of kawasaki disease | |
| Dal Negro et al. | A two-stage logistic model based on the measurement of pro-inflammatory cytokines in bronchial secretions for assessing bacterial, viral, and non-infectious origin of COPD exacerbations | |
| JP2013519082A5 (enExample) | ||
| Erturk et al. | Serum resistin levels may be new prognostic factor of Crimean-Congo hemorrhagic fever | |
| Azman et al. | C-reactive Protein, Albumin, Urea, CRP/Albumin Ratio, and Urea/Albumin ratio: A retrospective evaluation in COVID-19 patients |